Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy. 2021

Wenqing Li, and Xinfu Zhang, and Chengxiang Zhang, and Jingyue Yan, and Xucheng Hou, and Shi Du, and Chunxi Zeng, and Weiyu Zhao, and Binbin Deng, and David W McComb, and Yuebao Zhang, and Diana D Kang, and Junan Li, and William E Carson, and Yizhou Dong
Division of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, 43210, USA.

Antibodies targeting costimulatory receptors of T cells have been developed for the activation of T cell immunity in cancer immunotherapy. However, costimulatory molecule expression is often lacking in tumor-infiltrating immune cells, which can impede antibody-mediated immunotherapy. Here, we hypothesize that delivery of costimulatory receptor mRNA to tumor-infiltrating T cells will enhance the antitumor effects of antibodies. We first design a library of biomimetic nanoparticles and find that phospholipid nanoparticles (PL1) effectively deliver costimulatory receptor mRNA (CD137 or OX40) to T cells. Then, we demonstrate that the combination of PL1-OX40 mRNA and anti-OX40 antibody exhibits significantly improved antitumor activity compared to anti-OX40 antibody alone in multiple tumor models. This treatment regimen results in a 60% complete response rate in the A20 tumor model, with these mice being resistant to rechallenge by A20 tumor cells. Additionally, the combination of PL1-OX40 mRNA and anti-OX40 antibody significantly boosts the antitumor immune response to anti-PD-1 + anti-CTLA-4 antibodies in the B16F10 tumor model. This study supports the concept of delivering mRNA encoding costimulatory receptors in combination with the corresponding agonistic antibody as a strategy to enhance cancer immunotherapy.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D010743 Phospholipids Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system. Phosphatides,Phospholipid
D006017 Glycolipids Any compound containing one or more monosaccharide residues bound by a glycosidic linkage to a hydrophobic moiety such as an acylglycerol (see GLYCERIDES), a sphingoid, a ceramide (CERAMIDES) (N-acylsphingoid) or a prenyl phosphate. (From IUPAC's webpage) Glycolipid
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D016246 Lymphocytes, Tumor-Infiltrating Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer. Tumor Infiltrating Lymphocyte,Tumor-Derived Activated Cell,Tumor-Derived Activated Cells,Tumor-Infiltrating Lymphocyte,Tumor-Infiltrating Lymphocytes,Activated Cell, Tumor-Derived,Activated Cells, Tumor-Derived,Infiltrating Lymphocyte, Tumor,Infiltrating Lymphocytes, Tumor,Lymphocyte, Tumor Infiltrating,Lymphocyte, Tumor-Infiltrating,Lymphocytes, Tumor Infiltrating,Tumor Derived Activated Cell,Tumor Derived Activated Cells,Tumor Infiltrating Lymphocytes
D016503 Drug Delivery Systems Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity. Drug Targeting,Delivery System, Drug,Delivery Systems, Drug,Drug Delivery System,Drug Targetings,System, Drug Delivery,Systems, Drug Delivery,Targeting, Drug,Targetings, Drug
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Wenqing Li, and Xinfu Zhang, and Chengxiang Zhang, and Jingyue Yan, and Xucheng Hou, and Shi Du, and Chunxi Zeng, and Weiyu Zhao, and Binbin Deng, and David W McComb, and Yuebao Zhang, and Diana D Kang, and Junan Li, and William E Carson, and Yizhou Dong
June 2023, Pharmaceutics,
Wenqing Li, and Xinfu Zhang, and Chengxiang Zhang, and Jingyue Yan, and Xucheng Hou, and Shi Du, and Chunxi Zeng, and Weiyu Zhao, and Binbin Deng, and David W McComb, and Yuebao Zhang, and Diana D Kang, and Junan Li, and William E Carson, and Yizhou Dong
March 2020, Cellular immunology,
Wenqing Li, and Xinfu Zhang, and Chengxiang Zhang, and Jingyue Yan, and Xucheng Hou, and Shi Du, and Chunxi Zeng, and Weiyu Zhao, and Binbin Deng, and David W McComb, and Yuebao Zhang, and Diana D Kang, and Junan Li, and William E Carson, and Yizhou Dong
October 2020, Advanced materials (Deerfield Beach, Fla.),
Wenqing Li, and Xinfu Zhang, and Chengxiang Zhang, and Jingyue Yan, and Xucheng Hou, and Shi Du, and Chunxi Zeng, and Weiyu Zhao, and Binbin Deng, and David W McComb, and Yuebao Zhang, and Diana D Kang, and Junan Li, and William E Carson, and Yizhou Dong
July 1997, Proceedings of the National Academy of Sciences of the United States of America,
Wenqing Li, and Xinfu Zhang, and Chengxiang Zhang, and Jingyue Yan, and Xucheng Hou, and Shi Du, and Chunxi Zeng, and Weiyu Zhao, and Binbin Deng, and David W McComb, and Yuebao Zhang, and Diana D Kang, and Junan Li, and William E Carson, and Yizhou Dong
January 2021, International immunopharmacology,
Wenqing Li, and Xinfu Zhang, and Chengxiang Zhang, and Jingyue Yan, and Xucheng Hou, and Shi Du, and Chunxi Zeng, and Weiyu Zhao, and Binbin Deng, and David W McComb, and Yuebao Zhang, and Diana D Kang, and Junan Li, and William E Carson, and Yizhou Dong
February 2019, ACS applied materials & interfaces,
Wenqing Li, and Xinfu Zhang, and Chengxiang Zhang, and Jingyue Yan, and Xucheng Hou, and Shi Du, and Chunxi Zeng, and Weiyu Zhao, and Binbin Deng, and David W McComb, and Yuebao Zhang, and Diana D Kang, and Junan Li, and William E Carson, and Yizhou Dong
January 2021, Frontiers in immunology,
Wenqing Li, and Xinfu Zhang, and Chengxiang Zhang, and Jingyue Yan, and Xucheng Hou, and Shi Du, and Chunxi Zeng, and Weiyu Zhao, and Binbin Deng, and David W McComb, and Yuebao Zhang, and Diana D Kang, and Junan Li, and William E Carson, and Yizhou Dong
January 2019, Frontiers in immunology,
Wenqing Li, and Xinfu Zhang, and Chengxiang Zhang, and Jingyue Yan, and Xucheng Hou, and Shi Du, and Chunxi Zeng, and Weiyu Zhao, and Binbin Deng, and David W McComb, and Yuebao Zhang, and Diana D Kang, and Junan Li, and William E Carson, and Yizhou Dong
October 1995, Current opinion in immunology,
Wenqing Li, and Xinfu Zhang, and Chengxiang Zhang, and Jingyue Yan, and Xucheng Hou, and Shi Du, and Chunxi Zeng, and Weiyu Zhao, and Binbin Deng, and David W McComb, and Yuebao Zhang, and Diana D Kang, and Junan Li, and William E Carson, and Yizhou Dong
December 2017, Current opinion in biotechnology,
Copied contents to your clipboard!